Stock · VRTX · Healthcare
United States · Large Cap · listed since 1991 · Revenue 12 mo. $12.6B
Price as of 11/06/2026
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Original text from the data provider
Summary
55.3 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €2.9B (2025), it supports €31.8B. The remaining €93.9B of the market value assume it grows 19.1% a year for 10 years and not at all afterwards.
Required FCF growth per year
19.1%
no growth afterwards
Price to operating cash flow 32.6×, above its usual range.
Middle half of 16 quarters: 20.5× to 28.2×, median 23.8×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
7 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, EBIT margin, FCF margin, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 21.18% | 11.52% | Rank 80 |
| Return on capital (Greenblatt) | 45.68% | 32.55% | Rank 66 |
| EBIT margin | 39.43% | 18.31% | Rank 94 |
| FCF margin | 26.45% | 14.12% | Rank 87 |
| Gross margin | 85.03% | 60.99% | Rank 92 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 9.57% | 8.04% | Rank 59 |
| Earnings growth, 3 years per year | 6.12% | 5.44% | Rank 53 |
| Earnings growth, 5 years per year | 8.28% | 7.00% | Rank 55 |
| Sustainable growth (ROE × retained earnings) | 3.62% | 3.66% | Rank 49 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.80% | 2.90% | Rank 46 |
| FCF yield | 2.28% | 3.63% | Rank 26 |
| EV/saleslower is better | 11.38 | 4.03 | Rank 12 |
| EV/EBITlower is better | 28.86 | 21.73 | Rank 31 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 21.83% | 8.66% | Rank 69 |
| Share price, 6 months | 27.77% | 24.27% | Rank 59 |
| Share price, 3 months | 15.42% | 15.42% | Rank 50 |
| Distance from 52-week high | −2.11% | −7.35% | Rank 74 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 5.21% | 0.30% | Rank 18 |
| Change in share countlower is better | 0.04% | 0.00% | Rank 35 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | 0.05% | 0.05% | Rank 50 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 71.40% | 48.40% | Rank 81 |
| Net debt/EBITDAlower is better | −0.56 | 1.11 | Rank 78 |
| Debt to equitylower is better | 0.21 | 0.48 | Rank 71 |
| Volatility, 1 yearlower is better | 29.34% | 31.42% | Rank 65 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | 1.7 | 0.6% | $179.5M | 245M | −$345.7M |
| 2017 | 2.5 | 5.0% | $585.5M | 253M | −$1.1B |
| 2018 | 3.0 | 20.8% | $1.2B | 259M | −$2.1B |
| 2019 | 4.2 | 28.8% | $1.5B | 261M | −$2.4B |
| 2020 | 6.2 | 46.0% | $3.0B | 263M | −$5.1B |
| 2021 | 7.6 | 36.7% | $2.4B | 260M | −$5.8B |
| 2022 | 8.9 | 48.2% | $3.9B | 259M | −$9.6B |
| 2023 | 9.9 | 38.8% | $3.3B | 261M | −$9.6B |
| 2024 | 11.0 | −2.1% | −$790.3M | 258M | −$2.8B |
| 2025 | 12.1 | 39.4% | $3.2B | 258M | −$1.2B |
4 of 7 StockScorer Score rules met · How the score is built
Vertex Pharmaceuticals Inc mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Vertex Pharmaceuticals Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
4 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Vertex Pharmaceuticals Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 35.7 | 30.0 |
| P/B ratio | 7.6 | 4.8 |
| Return on equity (ROE) | 21.2% | 11.5% |
| Equity ratio | 71.4% | 48.4% |
| Debt-to-equity (D/E) | 0.21 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| VRTX | Vertex Pharmaceuticals Incthis page | |
| MRNA | Moderna Inc | Low0.9 |
| REGN | Regeneron Pharmaceuticals Inc | Medium5.5 |
| RVMD | Revolution Medicines Inc | locked |
| RPRX | Royalty Pharma Plc | locked |
| CSL.AX | CSL Ltd | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.